<p>Rapt Therapeutics（NASDAQ:RAPT - 获取免费报告）的股票在覆盖该公司的十四家券商中获得了 “适度买入” 的平均评级，MarketBeat 报告称。一位投资分析师对该股票给予了卖出建议，两位给予了持有建议，九位给予了买入建议，另外两位则对该公司给予了强烈买入建议。在过去一年中，对该股票发布评级的券商的平均一年目标价为 55.4444 美元。</p>
<p>RAPT 最近成为多份分析师报告的主题。富国银行在 11 月 3 日的研究报告中对 Rapt Therapeutics 设定了 72.00 美元的目标价，并给予该股票 “超配” 评级。Leerink Partners 在 9 月 25 日的研究报告中将 Rapt Therapeutics 的评级从 “持有” 上调至 “强烈买入”。摩根大通在 11 月 12 日的研究报告中将 Rapt Therapeutics 的目标价从 55.00 美元上调至 57.00 美元，并给予该公司 “超配” 评级。Cowen 在 12 月 18 日的研究报告中开始覆盖 Rapt Therapeutics 的股票，并对该公司设定了 “买入” 评级。最后，Piper Sandler 在周五的研究报告中开始覆盖 Rapt Therapeutics 的股票，并设定了 “超配” 评级和 95.00 美元的目标价。</p>
<p>获取 <strong>Rapt Therapeutics</strong> 的提醒：</p>
<p><strong>查看我们最新的 RAPT 股票分析</strong></p>
<h2>Rapt Therapeutics 的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近修改了他们对 RAPT 的持股。Velan Capital Investment Management LP 在第三季度收购了 Rapt Therapeutics 的新头寸，价值约为 2,063,000 美元。Susquehanna International Group LLP 在第三季度将其在 Rapt Therapeutics 的股份增加了 173.4%。Susquehanna International Group LLP 现在拥有 45,382 股该公司的股票，价值为 1,170,000 美元，此前在上个季度又收购了 28,782 股。Millennium Management LLC 在第三季度将其在 Rapt Therapeutics 的股份增加了 75.2%。Millennium Management LLC 现在拥有 39,278 股该公司的股票，价值为 1,013,000 美元，此前在此期间又收购了 16,854 股。Boone Capital Management LLC 在第三季度收购了 Rapt Therapeutics 的新头寸，价值约为 20,180,000 美元。最后，Ameriprise Financial Inc. 在第三季度收购了 Rapt Therapeutics 的新头寸，价值约为 1,326,000 美元。99.09% 的股票由机构投资者和对冲基金持有。</p>
<h2>Rapt Therapeutics 股票表现</h2>
<p>NASDAQ:RAPT 的股票在周三开盘价为 34.06 美元。该股票的 50 日简单移动平均线为 32.31 美元，200 日简单移动平均线为 22.63 美元。Rapt Therapeutics 的 52 周低点为 5.67 美元，52 周高点为 42.39 美元。该股票的市值为 9.438 亿美元，市盈率为-3.08，贝塔值为 0.45。</p>
<p>Rapt Therapeutics（NASDAQ:RAPT - 获取免费报告）最近在 11 月 6 日发布了其财报。该公司报告季度每股收益（EPS）为（0.65）美元，超出分析师共识预期的（0.88）美元，超出幅度为 0.23 美元。整体来看，股票分析师预测 Rapt Therapeutics 在当前财年将发布-2.14 的每股收益。</p>
<h2>关于 Rapt Therapeutics</h2>
<p>（获取免费报告）</p>
<p>RAPT Therapeutics, Inc NASDAQ: RAPT 是一家临床阶段的生物技术公司，开发用于自身免疫和过敏性疾病的新型治疗药物。公司成立于 2013 年，总部位于加利福尼亚州圣地亚哥，RAPT 应用组织选择性免疫学设计小分子和生物制剂候选药物，以调节免疫细胞的迁移和组织驻留途径。公司的研究平台能够识别驱动组织炎症的靶点，旨在实现比当前疗法更好的疗效和安全性。</p>
<p>公司的主要资产 RPT193 是一种口服可用的 CC 化学趋化因子受体 4（CCR4）拮抗剂，目前正在进行特应性皮炎和过敏性哮喘的临床开发。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过 Rapt Therapeutics</li>
<li>股票即将迎来 “凶兆日”……</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>将这些代码输入到您的普通经纪账户中</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
<li>特朗普刚刚签署了</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFQVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Rapt Therapeutics 吗？</h2>
<p>在你考虑 Rapt Therapeutics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Rapt Therapeutics 并不在名单上。</p>
<p>虽然 Rapt Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RAPT

<p>Rapt Therapeutics（纳斯达克代码：RAPT）获得了 14 家券商的 “适度买入” 共识评级。分析师的建议包括 1 个卖出、2 个持有、9 个买入和 2 个强力买入。1 年期的平均目标价格为 55.44 美元。最近的报告包括富国银行的 72 美元目标价和摩根大通将目标价上调至 57 美元。该股票开盘价为 34.06 美元，市值为 9.438 亿美元，52 周价格区间为 5.67 美元至 42.39 美元。Rapt 专注于开发针对自身免疫和过敏疾病的治疗药物，其主要资产 RPT193 正在进行临床开发</p>

<p>Shares of Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) have earned an average rating of &#34;Moderate Buy&#34; from the fourteen brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, nine have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $55.4444.</p>
<div class="lb-trans"><p>Rapt Therapeutics（NASDAQ:RAPT - 获取免费报告）的股票在覆盖该公司的十四家券商中获得了 “适度买入” 的平均评级，MarketBeat 报告称。一位投资分析师对该股票给予了卖出建议，两位给予了持有建议，九位给予了买入建议，另外两位则对该公司给予了强烈买入建议。在过去一年中，对该股票发布评级的券商的平均一年目标价为 55.4444 美元。</p>
</div><p>RAPT has been the subject of a number of recent analyst reports. Wells Fargo &amp; Company set a $72.00 price objective on Rapt Therapeutics and gave the stock an &#34;overweight&#34; rating in a research report on Monday, November 3rd. Leerink Partnrs upgraded Rapt Therapeutics from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, September 25th. JPMorgan Chase &amp; Co. boosted their price objective on Rapt Therapeutics from $55.00 to $57.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, November 12th. Cowen initiated coverage on shares of Rapt Therapeutics in a research report on Thursday, December 18th. They set a &#34;buy&#34; rating for the company. Finally, Piper Sandler started coverage on shares of Rapt Therapeutics in a research report on Friday. They set an &#34;overweight&#34; rating and a $95.00 price target on the stock.</p>
<div class="lb-trans"><p>RAPT 最近成为多份分析师报告的主题。富国银行在 11 月 3 日的研究报告中对 Rapt Therapeutics 设定了 72.00 美元的目标价，并给予该股票 “超配” 评级。Leerink Partners 在 9 月 25 日的研究报告中将 Rapt Therapeutics 的评级从 “持有” 上调至 “强烈买入”。摩根大通在 11 月 12 日的研究报告中将 Rapt Therapeutics 的目标价从 55.00 美元上调至 57.00 美元，并给予该公司 “超配” 评级。Cowen 在 12 月 18 日的研究报告中开始覆盖 Rapt Therapeutics 的股票，并对该公司设定了 “买入” 评级。最后，Piper Sandler 在周五的研究报告中开始覆盖 Rapt Therapeutics 的股票，并设定了 “超配” 评级和 95.00 美元的目标价。</p>
</div><p>Get <strong>Rapt Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Rapt Therapeutics</strong> 的提醒：</p>
</div><p><strong>View Our Latest Stock Analysis on RAPT</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 RAPT 股票分析</strong></p>
</div><h2>Institutional Trading of Rapt Therapeutics</h2>
<div class="lb-trans"><h2>Rapt Therapeutics 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of RAPT. Velan Capital Investment Management LP acquired a new position in Rapt Therapeutics in the third quarter valued at about $2,063,000. Susquehanna International Group LLP increased its position in shares of Rapt Therapeutics by 173.4% during the third quarter. Susquehanna International Group LLP now owns 45,382 shares of the company's stock valued at $1,170,000 after acquiring an additional 28,782 shares during the last quarter. Millennium Management LLC raised its stake in shares of Rapt Therapeutics by 75.2% in the 3rd quarter. Millennium Management LLC now owns 39,278 shares of the company's stock valued at $1,013,000 after acquiring an additional 16,854 shares during the period. Boone Capital Management LLC acquired a new position in shares of Rapt Therapeutics in the 3rd quarter worth approximately $20,180,000. Finally, Ameriprise Financial Inc. acquired a new position in shares of Rapt Therapeutics in the 3rd quarter worth approximately $1,326,000. 99.09% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近修改了他们对 RAPT 的持股。Velan Capital Investment Management LP 在第三季度收购了 Rapt Therapeutics 的新头寸，价值约为 2,063,000 美元。Susquehanna International Group LLP 在第三季度将其在 Rapt Therapeutics 的股份增加了 173.4%。Susquehanna International Group LLP 现在拥有 45,382 股该公司的股票，价值为 1,170,000 美元，此前在上个季度又收购了 28,782 股。Millennium Management LLC 在第三季度将其在 Rapt Therapeutics 的股份增加了 75.2%。Millennium Management LLC 现在拥有 39,278 股该公司的股票，价值为 1,013,000 美元，此前在此期间又收购了 16,854 股。Boone Capital Management LLC 在第三季度收购了 Rapt Therapeutics 的新头寸，价值约为 20,180,000 美元。最后，Ameriprise Financial Inc. 在第三季度收购了 Rapt Therapeutics 的新头寸，价值约为 1,326,000 美元。99.09% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Rapt Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Rapt Therapeutics 股票表现</h2>
</div><p>Shares of NASDAQ:RAPT opened at $34.06 on Wednesday. The stock's 50-day simple moving average is $32.31 and its two-hundred day simple moving average is $22.63. Rapt Therapeutics has a 52-week low of $5.67 and a 52-week high of $42.39. The stock has a market capitalization of $943.80 million, a price-to-earnings ratio of -3.08 and a beta of 0.45.</p>
<div class="lb-trans"><p>NASDAQ:RAPT 的股票在周三开盘价为 34.06 美元。该股票的 50 日简单移动平均线为 32.31 美元，200 日简单移动平均线为 22.63 美元。Rapt Therapeutics 的 52 周低点为 5.67 美元，52 周高点为 42.39 美元。该股票的市值为 9.438 亿美元，市盈率为-3.08，贝塔值为 0.45。</p>
</div><p>Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, topping analysts' consensus estimates of ($0.88) by $0.23. As a group, equities analysts forecast that Rapt Therapeutics will post -2.14 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Rapt Therapeutics（NASDAQ:RAPT - 获取免费报告）最近在 11 月 6 日发布了其财报。该公司报告季度每股收益（EPS）为（0.65）美元，超出分析师共识预期的（0.88）美元，超出幅度为 0.23 美元。整体来看，股票分析师预测 Rapt Therapeutics 在当前财年将发布-2.14 的每股收益。</p>
</div><h2>About Rapt Therapeutics</h2>
<div class="lb-trans"><h2>关于 Rapt Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>RAPT Therapeutics, Inc NASDAQ: RAPT is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company's research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.</p>
<div class="lb-trans"><p>RAPT Therapeutics, Inc NASDAQ: RAPT 是一家临床阶段的生物技术公司，开发用于自身免疫和过敏性疾病的新型治疗药物。公司成立于 2013 年，总部位于加利福尼亚州圣地亚哥，RAPT 应用组织选择性免疫学设计小分子和生物制剂候选药物，以调节免疫细胞的迁移和组织驻留途径。公司的研究平台能够识别驱动组织炎症的靶点，旨在实现比当前疗法更好的疗效和安全性。</p>
</div><p>The company's lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.</p>
<div class="lb-trans"><p>公司的主要资产 RPT193 是一种口服可用的 CC 化学趋化因子受体 4（CCR4）拮抗剂，目前正在进行特应性皮炎和过敏性哮喘的临床开发。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Rapt Therapeutics</li>
<li>“Ominous day” coming to stocks…</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Punch these codes into your ordinary brokerage account</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>Trump just signed it</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Rapt Therapeutics</li>
<li>股票即将迎来 “凶兆日”……</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>将这些代码输入到您的普通经纪账户中</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
<li>特朗普刚刚签署了</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFQVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=RAPT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rapt Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Rapt Therapeutics 吗？</h2>
</div><p>Before you consider Rapt Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Rapt Therapeutics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapt Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Rapt Therapeutics 并不在名单上。</p>
</div><p>While Rapt Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rapt Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

RAPT Therapeutics（纳斯达克代码：RAPT）被分析师一致评为 “适度买入”